Yasmin Schmid
Overview
Explore the profile of Yasmin Schmid including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
1186
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Noback M, Kenton J, Klein A, Hughes Z, Kruegel A, Schmid Y, et al.
Neuropharmacology
. 2025 Feb;
268:110334.
PMID: 39900138
Treating amotivated states remains difficult. Classical psychedelic drugs (5-HT receptor agonists) such as LSD and psilocybin have shown therapeutic potential in treating such symptoms, but their development has been hindered...
2.
Klaiber A, Humbert-Droz M, Ley L, Schmid Y, Liechti M
Br J Clin Pharmacol
. 2024 Nov;
PMID: 39587436
Aims: Psychedelics, including mescaline, may serve as novel treatments for depression and anxiety. However, data is scarce on the safety of mescaline. Methods: The present pooled analysis included two double-blind,...
3.
Klaiber A, Schmid Y, Becker A, Straumann I, Erne L, Jelusic A, et al.
Transl Psychiatry
. 2024 Sep;
14(1):395.
PMID: 39349427
Classic psychedelics have regained interest in research and therapy. Despite the long tradition of the human use of mescaline, modern data on its dose-dependent acute effects and pharmacokinetics are lacking....
4.
Schipper S, Nigam K, Schmid Y, Piechotta V, Ljuslin M, Beaussant Y, et al.
Cochrane Database Syst Rev
. 2024 Sep;
9:CD015383.
PMID: 39260823
Background: Psychedelic-assisted therapy refers to a group of therapeutic practices involving psychedelics taken under therapeutic supervision from physicians, psychologists, and others. It has been hypothesised that psychedelic-assisted therapy may reduce...
5.
Vizeli P, Studerus E, Holze F, Schmid Y, Dolder P, Ley L, et al.
Transl Psychiatry
. 2024 Sep;
14(1):357.
PMID: 39231959
The pharmacodynamic effects of lysergic acid diethylamide (LSD) are diverse and different in different individuals. Effects of other psychoactive substances have been shown to be critically influenced by non-pharmacological factors...
6.
Waters M, Dargan P, Yates C, Dines A, Eyer F, Giraudon I, et al.
Clin Toxicol (Phila)
. 2024 Jun;
62(6):378-384.
PMID: 38934347
Introduction: Cannabis is the most common recreational drug worldwide and synthetic cannabinoid receptor agonists are currently the largest group of new psychoactive substances. The aim of this study was to...
7.
Schmid Y, Bershad A
Biol Psychiatry Cogn Neurosci Neuroimaging
. 2024 Feb;
9(5):490-499.
PMID: 38341085
There has been renewed interest in the use of 3,4-methylenedioxy-methamphetamine (MDMA) and serotonergic psychedelics in the treatment of multiple psychiatric disorders. Many of these compounds are known to produce prosocial...
8.
Angerer V, Schmid Y, Franz F, Gnann H, Speer J, Gnann A, et al.
Drug Test Anal
. 2023 Dec;
16(9):1002-1011.
PMID: 38056906
The acute psychoactive, autonomic, and endocrine effects of the new psychoactive substance (NPS) 5,6-methylenedioxy-2-aminoindane (MDAI; 3.0 mg/kg, range 180-228 mg) were investigated in six healthy volunteers (four males, two females)...
9.
Vallersnes O, Dines A, Wood D, Heyerdahl F, Hovda K, Yates C, et al.
Int J Emerg Med
. 2023 Nov;
16(1):86.
PMID: 38030969
Background: Self-discharge is a risk factor for readmission and excess mortality. We assess the rate of self-discharge from the emergency department (ED) among presentations for acute recreational drug toxicity and...
10.
Lewis V, Bonniwell E, Lanham J, Ghaffari A, Sheshbaradaran H, Cao A, et al.
Cell Rep
. 2023 Mar;
42(3):112203.
PMID: 36884348
Hallucinations limit widespread therapeutic use of psychedelics as rapidly acting antidepressants. Here we profiled the non-hallucinogenic lysergic acid diethylamide (LSD) analog 2-bromo-LSD (2-Br-LSD) at more than 33 aminergic G protein-coupled...